{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:51:47Z","timestamp":1781607107507,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T00:00:00Z","timestamp":1345766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11102-012-0427-3","type":"journal-article","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T01:34:46Z","timestamp":1345685686000},"page":"608-613","source":"Crossref","is-referenced-by-count":29,"title":["Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review"],"prefix":"10.1007","volume":"15","author":[{"given":"Ilan","family":"Shimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Rot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Inbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,24]]},"reference":[{"key":"427_CR1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing\u2019s syndrome. Lancet 367:1605\u20131617","journal-title":"Lancet"},{"key":"427_CR2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479\u2013484","journal-title":"Clin Endocrinol (Oxf)"},{"key":"427_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/jc.86.1.117","volume":"86","author":"J Lindholm","year":"2001","unstructured":"Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing\u2019s syndrome: a population-based study. J Clin Endocrinol Metab 86:117\u2013123","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR4","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","volume":"88","author":"G Arnaldi","year":"2003","unstructured":"Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593\u20135602","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR5","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BMK Biller","year":"2008","unstructured":"Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR6","unstructured":"Korlym\u2122 (mifepristone) full prescribing information (2012) Corcept Therapeutics Inc"},{"key":"427_CR7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97:2039\u20132049","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR8","unstructured":"Signifor Summary of Product Characteristics (2012) Novartis Europharm Limited"},{"key":"427_CR9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BMK (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924","journal-title":"N Engl J Med"},{"key":"427_CR10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1517\/13543784.17.5.669","volume":"17","author":"KI Alexandraki","year":"2008","unstructured":"Alexandraki KI, Grossman AB (2008) Pituitary-targeted medical therapy of Cushing\u2019s disease. Expert Opin Investig Drugs 17:669\u2013677","journal-title":"Expert Opin Investig Drugs"},{"key":"427_CR11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707\u2013716","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"427_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000314296","volume":"92","author":"LJ Hofland","year":"2010","unstructured":"Hofland LJ, Lamberts SW, Feelders RA (2010) Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinology 92(Suppl 1):11\u201316","journal-title":"Neuroendocrinology"},{"key":"427_CR13","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482\u20134488","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, Van Der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645\u2013654","journal-title":"Eur J Endocrinol"},{"key":"427_CR15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary dependent Cushing\u2019s disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115\u2013122","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR16","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1210\/jc.83.5.1619","volume":"83","author":"L Katznelson","year":"1998","unstructured":"Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte ET, Hsu DW, Zervas NT, Swearingen B, Sleeper M, Klibanski A (1998) Biochemical assessment of Cushing\u2019s disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 83:1619\u20131623","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR17","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","volume":"93","author":"RD Murray","year":"2008","unstructured":"Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957\u20132968","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR18","unstructured":"Farrall A, Glusman JE, Ruffin M, Petersenn S (2008) Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from a Phase II extension study. Endocrine Abstracts 16:OC1.4"},{"key":"427_CR19","unstructured":"Bronstein MD, Sheppard M, Freda P, Gu F, Shen C-C, Gadelha M, Fleseriu M, Hermosillo Resendiz K, Ruffin M, Chen Y, Colao A (2012) Pasireotide LAR is significantly more effective than octreotide LAR at providing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study. Endocr Rev 33, abst OR49-3"},{"key":"427_CR20","doi-asserted-by":"crossref","first-page":"24011","DOI":"10.1074\/jbc.M501998200","volume":"280","author":"A Ben Shlomo","year":"2005","unstructured":"Ben Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S (2005) Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of ACTH secretion. J Biol Chem 280:24011\u201324021","journal-title":"J Biol Chem"},{"key":"427_CR21","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J Hoek Van Der","year":"2005","unstructured":"Van Der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:E278\u2013E287","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"427_CR22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1179\/174313208X289499","volume":"30","author":"M Kurosaki","year":"2008","unstructured":"Kurosaki M, Saegert W, Abe T, Ludecke DK (2008) Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 30:518\u2013522","journal-title":"Neurol Res"},{"key":"427_CR23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","volume":"17","author":"C Susini","year":"2006","unstructured":"Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733\u20131742","journal-title":"Ann Oncol"},{"key":"427_CR24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223\u2013230","journal-title":"J Clin Endocrinol Metab"},{"key":"427_CR25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med 362:1846\u20131848","journal-title":"N Engl J Med"},{"key":"427_CR26","doi-asserted-by":"crossref","unstructured":"Henry RR, Mudaliar S, Wetli-Hermosillo K, Ligueros-Saylan M, Chenji S, Golor G (2011) Mechanism and management of hyperglycemia associated with pasireotide: Results from studies in healthy volunteers. Endocr Rev 32(03), abst P3-274","DOI":"10.1210\/endo-meetings.2011.PART3.P30.P3-274"},{"issue":"Suppl 1","key":"427_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000314292","volume":"92","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, Hofland LJ, de Herder WW (2010) Medical treatment of Cushing\u2019s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 92(Suppl 1):111\u2013115","journal-title":"Neuroendocrinology"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-012-0427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-012-0427-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-012-0427-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T22:21:11Z","timestamp":1562106071000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-012-0427-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,24]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1007\/s11102-012-0427-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718205963.793488573","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,24]]}}}